Sanofi’s Jevtana® (cabazitaxel) Not Obvious over Docetaxel Sanofi-Aventis U.S., LLC v. Fresenius Kabi USA, LLC (Fed. Cir. 2019) CAFC Panel: Circuit Judges Lourie, Moore, and Taranto Opinion by Circuit Judge Lourie See Patent Doc’s Post: https://www.patentdocs.org/2019/08/sanofi-aventis-us-llc-v-dr-reddys-laboratories-inc-fed-cir-2019.html https://www.jevtana.com/ Share: Share on X (Opens in new window) X Share on Facebook (Opens in new window) Facebook Share on LinkedIn (Opens in new window) LinkedIn Print (Opens in new window) Print Idenix v. Gilead: Split CAFC Panel at Least Agrees – Valid or Not, Either Way it’s Idenix Loss – Claims Too BroadDateFebruary 4, 2023In relation toCase LawInherency & Therapeutic Mechanisms: Reviewing In re Couvaras – (With No-Frills Diagrams)DateJuly 27, 2023In relation toCase LawSmall Molecule Lens for Viewing Amgen v. SanofiDateJune 26, 2023In relation toCase Law
